Neurosurgeons are familiar with ankylosing spondylitis (AS) as a chronic, immune-mediated disease characterized by inflammation and new bone formation in the axial spine, resulting in autofusion of the spinal column susceptible to Chance fractures.1
Patients with AS are more familiar with the considerable pain and the poor quality of life that results from diffuse arthritic and sacroiliac pain.2With historically few specific treatment options, a new class of medications is being designed and used for conditions that once had no treatment. . .
Full text access is available to all readers.